It has been speculated that the modified form of plasminogen, a precursor of proteolytic enzyme plasmin in plasma, plays an important role in fibrinolysis in the blood. The present study was undertaken to examine the production by a2-macroglobulin-plasmin complexes. a2-macroglobulin-plasmin complexes were purified from urokinase-activated plasma by affinity chromatography on lysine-Sepharose and gel filtration on Ultrogel AcA 22. The plasmin complex converted native plasminogen into the modified form more easily in the presence of s-aminocaproic acid.
role in fibrinolysis in the blood. The present study was undertaken to examine the production by a2-macroglobulin-plasmin complexes. a2-macroglobulin-plasmin complexes were purified from urokinase-activated plasma by affinity chromatography on lysine-Sepharose and gel filtration on Ultrogel AcA 22. The plasmin complex converted native plasminogen into the modified form more easily in the presence of s-aminocaproic acid.
The modification of native plasminogen by a2-macroglobulin-bound plasmin was completely inhibited by aprotinin, and partly by soybean trypsin inhibitor. a2-macroglobulin-bound plasmin produced modified plasminogen in human plasma where potent plasmin inhibitors exist, though the degree of production was small. The present results support the speculation of the important role of the modified form in vivo.
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It has been reported that fibrin clot may be dissolved by plasmin derived from plasminogen adsorbed on fibrin in circulating blood (ALKJAERSIG et al., 1959; AOKI and HARPEL, 1984) . The native form of human plasminogen is a zymogen with NH2-terminal glutamic acid (WALLEN and WIMAN,1970; RICKLI and CUENDET, 1971; BOBBINS et al., 1972) . This form is converted by plasmin into a modified form with a NH2-terminal lysine releasing peptides from the NH2-terminal portion (CLAEYS et al., 1973; SUMMARIA et a!., 1975; VIOLAND and CASTELLINO, 1976) . The modified form has a stronger affinity for fibrin (THORSEN,1975) and is more easily activated by a plasminogen activator than the native form (CLAEYS and VERMYLEN, 1974; THORSEN et al., 1974) . These properties of the modified form support the above hypothesis on fibrin clot dissolution.
Plasmin is inactivated primarily by a2-plasmin inhibitor (a2PI) and secon-darily by a2-macroglobulin (a2M) in plasma (AOKI and HARPEL,1984) . a2M is an interesting proteinase inhibitor, because the activity of a2M-bound plasmin is decreased, but not abolished. The present study was undertaken to examine the conversion of native plasminogen into a modified form by a2M-bound plasmin, a2M-plasmin complexes.
MATERIALS AND METHODS
Materials. Fresh-frozen human plasma was prepared from the citrated blood
(1 vol. 3.8 % Na-citrate to 9 vol, blood) of healthy adult volunteers, without glassware, to avoid contact-activation, pooled (n-50), and stored at -80°C until use. Human native plasminogen was purified from pooled, fresh frozen plasma by affinity chromatography and gel filtration. Plasma (100 ml) was applied to a lysine-Sepharose column (10 ml bed volume) that had been equilibrated with a phosphate buffer containing 1.5 M NaCI. The column was washed with the same buffer until absorbance at 280 nm was below 0.03, and then washed with phosphatebuffered saline (PBS, 10 ml, 10 times). Plasminogen was eluted with PBS, containing 0.025 M r-aminocaproic acid (EACA, 10 ml, 4 times), and precipitated by ammonium sulphate (50% saturation) at 4°C, overnight. The precipitate was dissolved in 10 ml of PBS. The solution was gel-filtrated on an Ultrogel AcA 44 column (1.6 x 65 cm) at 4°C after treatment with diisopropyl fluorophosphoridate (DFP, final conc. 0.01 M) for 30 min in an ice-bath. Eluted plasminogen was pooled and reprecipitated with ammonium sulphate (50% saturation). The precipitate was dissolved in an appropriate volume of PBS, dialysed against PBS, and kept at -80°C until use. Native plasminogen was identified by electrophoresis on polyacrylamide gel containing EACA.
Bovine plasminogen was purified from citrated blood by the same method as with human native plasminogen.
Bovine fibrinogen (0.33 %) (Miles Laboratories Inc., U.S.A.) dissolved in 0.1 M Tris-HC1 (pH 8.0) was passed through a lysine-Sepharose column to remove plasminogen. The solution was stored at -80°C until use.
Bovine thrombin (Mochida Pharmaceutical Co., Ltd., Japan) was dissolved in 0.1 M Tris-HC1 (pH 8.0) at a concentration of 10 units/ml. The solution was stored at -80°C until use.
Urokinase (UK, Green Cross Co., Ltd., Japan) was dissolved in saline immediately before use and kept in an ice-bath.
Streptokinase (Varidase, Lederle Laboratories) was dissolved in 0.1 M TirsHCl (pH 8.0) at a concentration of 5,000 units/ml. The solution was stored at -80°C until use .
Lysine-Sepharose was prepared according to the method of DEUTSCH and MERTZ (1970) .
Aprotinin was a product of Bayer, Germany (Trasylol, 10,000 KIU/ml, 220 ,uM). Soybean trypsin inhibitor (STI, Sigma, Type I-S) was dissolved in PBS at a concentration of 250 uM.
PBS was prepared by dissolving 0.14 M NaCI in 0.01 M potassium phosphate buffer (pH 7.4).
Phosphate buffer containing 1.5 M NaCI (PB-NaCI) was prepared by dissolving 1.5 M NaCI in 0.01 M potassium phosphate buffer (pH 7.4).
DFP (Sigma, U.S.A.) was dissolved in isopropyl alcohol at a concentration of 1 M.
All reagents were of reagent grade. Methods. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed by essentially the same method reported by WEBER and OsBORN (1969) , using unreduced gel (3.5 %). Details have been described elsewhere (YAMAMOTo et al., 1982) .
Electrophoresis on polyacrylamide gel containing EACA (EACA-PAGE) was performed by essentially the same method reported by SUMMARIA et al. (1972) . In the present study, slab gel was replaced by a 5 % disc gel. Samples were mixed with 1/4 volume of myoglobin (0.5 mg/ml 50 % sucrose), and 0.3 ml of the mixture per gel was run (YAMAMOTO et al., 1982) .
Zymography was carried out according to the method of WALLEN and WIMAN (1970) .
The concentration of protein was determined by measuring the absorbance at 280 nm using a Hitachi spectrophotometer model 200-10 (Japan). Molar concentrations of purified plasminogen, a2M, and a2M-plasmin complexes were estimated using the extinction coefficients (El m) of 17.1, 8.1, and 8.1, and molecular weights of 90,000, 725,000, and 653,000, respectively.
Concentration of a2M-plasmin fraction was performed in a dialysing bag covered with polyethylene glycol powder (Carbowax 20,000, Nakarai Chem., Ltd., Japan) and kept at 4°C. The concentrate of a2M-plasmin complexes was kept at -80°C until use .
The densities of bands on the disc gel were determined with a densitometer (Shimadzu chromatoscanner CS-930, Japan).
RESULTS

Preparation of a2M plasmin complexes
Fresh-frozen human plasma (50 ml) was activated by UK (5 ml, 5,000 IU/ml) for 30 min at 37.5°C. The mixture was applied to a lysine-Sepharose column (5 ml bed volume). The column was washed with PB-NaC1 and PBS, as described above. The adsorbed fraction, containing a2M-plasmin complexes, a2PI-plasmin complex, and a small amount of plasminogen, was eluted with PBS containing 0.025 M EACA (5 ml, 4 times). The eluted fraction (a2M-plasmin complexes prep-aration I) was gel-filtrated on an Ultrogel AcA 22, and each fraction was analyzed by SDS-PAGE (Fig. 1) .
a2M-plasmin complexes were separated from a2PI-plasmin complex and plasminogen. However, each of the a2M-plasmin complexes with different molecular weights was not separated (a in Fig. 1B ). Bands in a in Fig. l B have been shown previously to be a2M-plasmin complexes (YAMAMOTO and OKAMOTO 1985) . Fractions containing a2M-plasmin complexes indicated in Fig. lA (a2M-plasmin com- plexes preparation II) were pooled, concentrated, dialysed against PBS and kept at -80°C until use.
Conversion of native plasminogen into a mod fled form by a2M plasmin complexes a2M-plasmin complexes preparation 1(1 ml), containing 0.025 M EACA, was incubated with native plasminogen (1 ml, final conc. 3.9 µM) at 37.5°C for 0 min and 4 h. After incubation, the mixture was placed in an ice-bath, then aprotinin (15 µl) and DFP (3 ,ccl) were added. The mixture was allowed to stand in an icebath for 30 min. The sample was analyzed by EACA-PAGE. Results are shown in Fig. 2 .
New bands with slow migration appeared after treatment with a2M-plasmin complexes, showing plasminogen activity. These bands are the same as the previously described modified plasminogen produced in post-exercise blood and in UK-activated plasma (YAMAM0T0 et al., 1982 (YAMAM0T0 et al., , 1983 (YAMAM0T0 et al., , 1984 .
Effect of EACA on conversion of native plasminogen into a modified form by a2M plasmin complexes Native plasminogen (1 ml, final conc. 3.8 ,uM) was incubated with an equal Japanese Journal of Physiology Fig. 1 . Gel filtration pattern of a2M-plasmin complexes preparation 1(A) and electrophoretic pattern of the fraction obtained by gel filtration (B). A) a2M-plasmin complexes preparation 1(20 ml) from 50 ml plasma was applied to an Ultrogel AcA 22 column, 3.0 x 57 cm. Elution was performed at a flow rate of 18 ml f h at 4°C. 5 ml fraction was collected. Elution buffer, PBS. B) Fractions indicated by arrows, 1 to 6, in A were analyzed on 3.5 % unreduced SDS-polyacrylamide gel. Migration, from top to bottom. a, a2M-plasmin complexes; b, cr2PI-plasmin complex; c, plasminogen.
volume of a2M-plasmin complexes preparation II (final conc. 0.92 µM) in the presence or absence of EACA (1 M in PBS, 27 ul, final conc. 12 mM) for 0 min or 4 h at 37.5°C. After incubation, aprotinin (15 ,ul) and DFP (3 µl) were added to the mixture, and the mixture was allowed to stand in an ice-bath for 30 min. Samples were analyzed by EACA-PAGE. Results are shown in Fig. 3 . Production of modified plasminogen was accelerated by EACA. Vol. 35, No. 6, 1985 Fig. 2. Conversion of native plasminogen into a modified form by a2M-plasmin complexes. A) Stained gel. B) Zymogram : electrophoresed gels were cut longitudinally and placed on a fibrin plate containing bovine plasminogen and streptokinase. After incubation, the plate was stained and destained. Lysed zones, white in blue black background, were seen. a, modified plasminogen; b, native plasminogen; c, a2PI-plasmin complex and a2M-plasmin complexes; d, marker protein (myoglobin).
Incubation time: 0 min
(1) and 4 h (2). Migration, from top to bottom. Effect of proteinase inhibitors on conversion of native plasminogen into a modified form by a2M plasmin complexes Aprotinin or STI (60 ul) was preincubated with a2M-plasmin complexes preparation 11 (300 ul, 1.9 , tM) for 10 min at 37.5°C. Native plasminogen (300 µl, 7.8 ,AM) and EACA (8 tl, 1 M) were added to the mixture, which was incubated for 4 h at 37.5°C. Production of modified plasminogen was estimated by EACA-PAGE. Results are shown in Fig. 4 .
Native plasminogen was converted into a modified form by a2M-plasmin complexes in the absence of inhibitors (gel 1), but not in the presence of aprotinin (gel 2). The pattern of gel 3 was different from that of gel 2, i.e. modified plasminogen bands were not observed, but some native plasminogen bands disappeared or became faint. Probably, modified plasminogen could not be observed because of its smaller amount. These results indicate that the lower molecular weight proteinase inhibitor, aprotinin with a molecular weight of 6,512, completely inhibits the conversion of native plasminogen, but the higher molecular weight proteinase inhibitor, STY with a molecular weight of 20,100, partly inhibits the conversion. Therefore, it was speculated that a2M-plasmin complexes can produce modified plasminogen in plasma, i.e. in the presence of a2PI with a molecular weight of 67,000.
Production of modified plasminogen by a2M plasmin complexes in plasma Fresh-frozen plasma (4 ml) was incubated with a2M-plasmin complexes preparation 11 (0.65 ml, 1.9 /AM) at 37.5°C overnight and the mixture was applied to a lysine-Sepharose column (0.5 ml bed volume). The column was washed with PBNaCI and PBS, as described above. Adsorbed proteins were eluted with PBS containing 0.025 M EACA (0.5 ml, 4 times). The eluted fractions were analyzed by EACA-PAGE. Results are shown in (1); native plasminogen, a2M-plasmin complexes, and aprotinin (2); native plasminogen, a2M-plasmin complexes and STI (3); native plasminogen (4); a2M-plasmin complexes (5); aprotinin (6); and STI (7). Other components were replaced by PBS, if not stated. a, modified plasminogen; b, native plasminogen; c, a2M-plasmin complexes.
Modified plasminogen could be produced by a2M-plasmin complexes in plasma, though the quantity was very small.
DISCUSSION
Plasminogen in the circulation is native plasminogen with NH2-terminal glutamic acid, which has less affinity for fibrin than a modified, or a partially degraded form with NH2-terminal lysine. Fibrin-bound plasminogen, responsible for dissolution of fibrin is considered to be a modified form because of its properties.
However, it has also been postulated that there is little possibility plasmin can substantially convert native plasminogen into a modified form in the presence of a2PI, because a2PI inactivates plasmin instantaneously (MoRol and AoKI, 1976; COLLEN, 1976; MULLERTZ and CLEMMENSEN, 1976; WIMAN and COLLEN, 1977) . Production of modified plasminogen, however, was shown in the presence of a2PI; i.e. in the plasma activated by UK and in the blood after strenuous exercise. Also, the production by free plasmin was suggested (YAMAMOTO et a!.,1983 (YAMAMOTO et a!., ,1984 . The production was confirmed by MULLERTZ et al. (1984) , but they neglected it because of the small amount involved. However, TOKI et al. (1985) estimated a large amount of the production in the blood after oral administration of clinicaltype high molecular weight UK.
Plasmin is inactivated primarily by a2PI and secondarily by a2M in plasma. Vol. 35, No. 6, 1985 But a considerable amount of a2M-plasmin complexes were found in the plasma activated by UK (HARPEL, 1981) , a2M-bound plasmin decreases its activity on high molecular weight substrates such as fibrinogen and fibrin, but retains it on low molecular weight substrates (HARPEL and MOSESSON,1973; VEREMEENKO and KIZIM, 1981) . Therefore, plasmin can be seen to retain its activity in a a2M-bound form in the presence of a2PI. The present study was undertaken to estimate production of modified plasminogen by a2M-plasmin complexes. a2M-plasmin complexes could convert native plasminogen into a modified form even in plasma, though the conversion was slight. a2M-plasmin complexes might increase the conversion in plasma under certain conditions, as suggested by AOKI and HARPEL (1984) .
Production of modified plasminogen by a2M-plasmin complexes were accelerated in the presence of EACA. The relation between the acceleration and concentration of EACA remains to be clarified. However, histidine-rich glycoprotein might act as an accelerator in plasma, because the protein has a similar effect to that of EACA (LIJNEN et al., 1980) .
